Physician profile
Kimberly Behney
NPI 1780208090
$1,686.52
in general payments reported to CMS, 2019-2025
16 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $240 · 2022: $473 · 2023: $380 · 2024: $101 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $525.58 | 2021-2024 | |
| Janssen Biotech, INC. | $205.37 | 2022-2023 | Remicade, Stelara, Simponi |
| Lilly USA, LLC | $199.95 | 2021-2025 | Zepbound, Mounjaro |
| Dexcom, INC. | $155.21 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $139.16 | 2021-2025 | Farxiga |
| Novo Nordisk INC | $127.95 | 2021-2025 | Ozempic |
| Medtronic, INC. | $106.27 | 2021-2025 | Minimed 780g |
| Takeda Pharmaceuticals U.S.A., INC. | $64.88 | 2023 | Entyvio, Gattex |
| Xeris Pharmaceuticals, INC. | $39.14 | 2021-2025 | Gvoke Hypopen |
| Ibsa Pharma INC. | $24.87 | 2025 | Tirosint, Licart, Flector |
| Zealand Pharma US, INC. | $21.19 | 2022 | |
| Tandem Diabetes Care, INC. | $19.60 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $16.70 | 2025 | Isturisa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.92 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.82 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $11.91 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Behney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.